Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma
暂无分享,去创建一个
Craig W. Reynolds | E. Jaffe | P. Duffey | D. Longo | L. Kwak | R. Pennington | F. A. Benko | C. Gocke | B. Gause | S. Creekmore | M. Bendandi | L. Sternås | C. Kobrin | T. Watson
[1] A. López-Guillermo,et al. The clinical significance of molecular response in indolent follicular lymphomas. , 1998, Blood.
[2] F. Marincola,et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.
[3] E. Gilboa,et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA , 1998, Nature Biotechnology.
[4] J. Fagerberg,et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. , 1998, Blood.
[5] T. Kipps,et al. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. , 1998, The Journal of clinical investigation.
[6] H. Rammensee,et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. , 1998, Cancer research.
[7] F. Brasseur,et al. A CASP-8 Mutation Recognized by Cytolytic T Lymphocytes on a Human Head and Neck Carcinoma , 1997, The Journal of experimental medicine.
[8] J. Gribben,et al. Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. , 1997, Blood.
[9] D. Czerwinski,et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial. , 1997, Blood.
[10] J. Schlom,et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. , 1997, Journal of the National Cancer Institute.
[11] L. Kwak,et al. Development of vaccine strategies for the treatment of B-cell malignancies. , 1997, Cancer investigation.
[12] H. Young,et al. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[13] A. Krensky,et al. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. , 1996, Blood.
[14] Edgar G. Engleman,et al. Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.
[15] J. Gribben,et al. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[16] P. Duffey,et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor , 1995, The Lancet.
[17] S. Beissert,et al. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? , 1995, Immunology today.
[18] J. Sklar,et al. Gamma delta T cell recognition of tumor Ig peptide. , 1995, Journal of immunology.
[19] E. Jaffee,et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[20] R. Levy,et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. , 1992, The New England journal of medicine.
[21] N. Arnheim,et al. Using the polymerase chain reaction to estimate mutation frequencies and rates in human cells. , 1992, Mutation research.
[22] J. Gribben,et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. , 1991, Blood.
[23] P. Greenberg. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. , 1991, Advances in immunology.
[24] E J Freireich,et al. Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. , 1987, Science.
[25] S. Rosenberg,et al. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. , 1987, Journal of immunology.
[26] R. Warnke,et al. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. , 1985, The New England journal of medicine.
[27] M. Raffeld,et al. Spontaneous alteration of idiotype in a monoclonal B-cell lymphoma. Escape from detection by anti-idiotype. , 1985, The New England journal of medicine.
[28] R. Fisher,et al. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. , 1983, Annals of internal medicine.
[29] D. Taramelli,et al. Measurement of macrophage-mediated cytotoxicity against adherent and non-adherent target cells by release of 11 indium-oxine. , 1981, Journal of immunological methods.
[30] F. Stevenson,et al. Antibody to a molecularly-defined antigen confined to a tumour cell surface , 1975, Nature.
[31] H. Eisen,et al. Myeloma proteins as tumor-specific transplantation antigens. , 1972, Proceedings of the National Academy of Sciences of the United States of America.